Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants
Identifieur interne : 001A24 ( PascalFrancis/Corpus ); précédent : 001A23; suivant : 001A25Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants
Auteurs : Judith Trotman ; Marion Fournier ; Thierry Lamy ; John Francis Seymour ; Anne Sonet ; Andrea Janikova ; Ofer Shpilberg ; Emmanuel Gyan ; Hervé Tilly ; Jane Estell ; Cecily Forsyth ; Didier Decaudin ; Bettina Fabiani ; Jean Gabarre ; Bruno Salles ; Eric Van Den Neste ; Danielle Canioni ; Etienne Garin ; Michael Fulham ; Thierry Vander Borght ; Gilles SallesSource :
- Journal of clinical oncology [ 0732-183X ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose The utility of [18F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study. Patients and Methods Results of PET-CT scans performed after induction immunochemotherapy were recorded retrospectively. Patients went on to either observation or rituximab maintenance per protocol independent of the PET-CT result. Patient characteristics and outcomes were then evaluated. Results Of 122 PET-CT scans performed at the end of the induction immunochemotherapy, 32 (26%) were reported as positive by the local investigator. Initial demographic or disease characteristics did not differ between PET-CT-positive (PET-positive) and PET-CT-negative (PET-negative) patients. PET status correlated with conventional response criteria (P<.001). Patients remaining PET positive had a significantly (P< .001) inferior progression-free survival at 42 months of 32.9% (95% CI, 17.2% to 49.5%) compared with 70.7% (95% CI, 59.3% to 79.4%) in those who became PET negative. PET status, but not conventional response (complete response or complete response unconfirmed v partial response) according to IWC 1999, was an independent predictive factor for lymphoma progression. The risk of death was also increased in PET-positive patients (hazard ratio 7.0; P = .0011). Conclusion [18F]FDG PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 11-0380678 INIST |
---|---|
ET : | Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants |
AU : | TROTMAN (Judith); FOURNIER (Marion); LAMY (Thierry); SEYMOUR (John Francis); SONET (Anne); JANIKOVA (Andrea); SHPILBERG (Ofer); GYAN (Emmanuel); TILLY (Hervé); ESTELL (Jane); FORSYTH (Cecily); DECAUDIN (Didier); FABIANI (Bettina); GABARRE (Jean); SALLES (Bruno); DEN NESTE (Eric Van); CANIONI (Danielle); GARIN (Etienne); FULHAM (Michael); BORGHT (Thierry Vander); SALLES (Gilles) |
AF : | Concord Hospital/Inconnu (1 aut., 10 aut.); Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney/Sydney/Australie (19 aut.); Peter MacCallum Cancer Center and University of Melbourne/Melbourne/Australie (4 aut.); Wyong Hospital/Kanwal/Australie (11 aut.); Hospices Civils de Lyon, Groupe d'Etude des Lymphomes de l'Adulte, Recherche Clinique, Hôpital Lyon sud, Pierre-Benite/France (2 aut.); Centre Hospitalier Universitaire (CHU) de Rennes, L'Institut National de la Sante et de la Recherche Médicale (INSERM) U917, Universite de Rennes/France (3 aut.); CHU de Rennes/Rennes/France (18 aut.); CHU de Tours/Tours/France (8 aut.); Centre Henri Becquerel, INSERM U918, Universite de Rouen/Rouen/France (9 aut.); Institut Curie/France (12 aut.); Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine/France (13 aut.); Hôpital de la Pitie Salpetriere/France (14 aut.); Hôpital Necker/Paris/France (17 aut.); Centre Hospitalier/Chalons-Saône/France (15 aut.); Hospices Civils de Lyon, Universite Lyon1/France (21 aut.); Universite Catholique de Louvain (UCL), Mont-Godinne Medical Center/Yvoir/France (5 aut., 20 aut.); UCL Saint-Luc/Brussels/Belgique (16 aut.); University Hospital Brno/Brno/Tchèque, République (6 aut.); Rabin Medical Center/Petah-Tikva/Israël (7 aut.); Tel Aviv University/Tel Aviv/Israël (7 aut.) |
DT : | Publication en série; Compte-rendu; Niveau analytique |
SO : | Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2011; Vol. 29; No. 23; Pp. 3194-3200; Bibl. 29 ref. |
LA : | Anglais |
EA : | Purpose The utility of [18F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study. Patients and Methods Results of PET-CT scans performed after induction immunochemotherapy were recorded retrospectively. Patients went on to either observation or rituximab maintenance per protocol independent of the PET-CT result. Patient characteristics and outcomes were then evaluated. Results Of 122 PET-CT scans performed at the end of the induction immunochemotherapy, 32 (26%) were reported as positive by the local investigator. Initial demographic or disease characteristics did not differ between PET-CT-positive (PET-positive) and PET-CT-negative (PET-negative) patients. PET status correlated with conventional response criteria (P<.001). Patients remaining PET positive had a significantly (P< .001) inferior progression-free survival at 42 months of 32.9% (95% CI, 17.2% to 49.5%) compared with 70.7% (95% CI, 59.3% to 79.4%) in those who became PET negative. PET status, but not conventional response (complete response or complete response unconfirmed v partial response) according to IWC 1999, was an independent predictive factor for lymphoma progression. The risk of death was also increased in PET-positive patients (hazard ratio 7.0; P = .0011). Conclusion [18F]FDG PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies. |
CC : | 002B04; 002B19B |
FD : | Tomoscintigraphie; Tomographie par émission de positons; Traitement induction; Tomodensitométrie; Homme; Pronostic; Lymphome folliculaire; Essai clinique; Cancérologie; Hémopathie maligne lymphoïde; Hémopathie lymphoïde B |
FG : | Exploration radioisotopique; Imagerie médicale; Radiodiagnostic; Hémopathie maligne; Cancer; Lymphome non hodgkinien; Syndrome lymphoprolifératif |
ED : | Emission tomography; Positron emission tomography; Induction treatment; Computerized axial tomography; Human; Prognosis; Follicular lymphoma; Clinical trial; Cancerology; Lymphoid neoplasm; B cell neoplasm |
EG : | Radionuclide study; Medical imagery; Radiodiagnosis; Malignant hemopathy; Cancer; Non Hodgkin lymphoma; Lymphoproliferative syndrome |
SD : | Tomocentelleografía; Tomografía emisión positrones; Tratamiento inductivo; Tomodensitometría; Hombre; Pronóstico; Linfoma folicular; Ensayo clínico; Cancerología |
LO : | INIST-20094.354000191138370140 |
ID : | 11-0380678 |
Links to Exploration step
Pascal:11-0380678Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants</title>
<author><name sortKey="Trotman, Judith" sort="Trotman, Judith" uniqKey="Trotman J" first="Judith" last="Trotman">Judith Trotman</name>
<affiliation><inist:fA14 i1="01"><s1>Concord Hospital</s1>
<s3>INC</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fournier, Marion" sort="Fournier, Marion" uniqKey="Fournier M" first="Marion" last="Fournier">Marion Fournier</name>
<affiliation><inist:fA14 i1="05"><s1>Hospices Civils de Lyon, Groupe d'Etude des Lymphomes de l'Adulte, Recherche Clinique, Hôpital Lyon sud, Pierre-Benite</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lamy, Thierry" sort="Lamy, Thierry" uniqKey="Lamy T" first="Thierry" last="Lamy">Thierry Lamy</name>
<affiliation><inist:fA14 i1="06"><s1>Centre Hospitalier Universitaire (CHU) de Rennes, L'Institut National de la Sante et de la Recherche Médicale (INSERM) U917, Universite de Rennes</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name>
<affiliation><inist:fA14 i1="03"><s1>Peter MacCallum Cancer Center and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sonet, Anne" sort="Sonet, Anne" uniqKey="Sonet A" first="Anne" last="Sonet">Anne Sonet</name>
<affiliation><inist:fA14 i1="16"><s1>Universite Catholique de Louvain (UCL), Mont-Godinne Medical Center</s1>
<s2>Yvoir</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Janikova, Andrea" sort="Janikova, Andrea" uniqKey="Janikova A" first="Andrea" last="Janikova">Andrea Janikova</name>
<affiliation><inist:fA14 i1="18"><s1>University Hospital Brno</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shpilberg, Ofer" sort="Shpilberg, Ofer" uniqKey="Shpilberg O" first="Ofer" last="Shpilberg">Ofer Shpilberg</name>
<affiliation><inist:fA14 i1="19"><s1>Rabin Medical Center</s1>
<s2>Petah-Tikva</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="20"><s1>Tel Aviv University</s1>
<s2>Tel Aviv</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gyan, Emmanuel" sort="Gyan, Emmanuel" uniqKey="Gyan E" first="Emmanuel" last="Gyan">Emmanuel Gyan</name>
<affiliation><inist:fA14 i1="08"><s1>CHU de Tours</s1>
<s2>Tours</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tilly, Herve" sort="Tilly, Herve" uniqKey="Tilly H" first="Hervé" last="Tilly">Hervé Tilly</name>
<affiliation><inist:fA14 i1="09"><s1>Centre Henri Becquerel, INSERM U918, Universite de Rouen</s1>
<s2>Rouen</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Estell, Jane" sort="Estell, Jane" uniqKey="Estell J" first="Jane" last="Estell">Jane Estell</name>
<affiliation><inist:fA14 i1="01"><s1>Concord Hospital</s1>
<s3>INC</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Forsyth, Cecily" sort="Forsyth, Cecily" uniqKey="Forsyth C" first="Cecily" last="Forsyth">Cecily Forsyth</name>
<affiliation><inist:fA14 i1="04"><s1>Wyong Hospital</s1>
<s2>Kanwal</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Decaudin, Didier" sort="Decaudin, Didier" uniqKey="Decaudin D" first="Didier" last="Decaudin">Didier Decaudin</name>
<affiliation><inist:fA14 i1="10"><s1>Institut Curie</s1>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fabiani, Bettina" sort="Fabiani, Bettina" uniqKey="Fabiani B" first="Bettina" last="Fabiani">Bettina Fabiani</name>
<affiliation><inist:fA14 i1="11"><s1>Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine</s1>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabarre, Jean" sort="Gabarre, Jean" uniqKey="Gabarre J" first="Jean" last="Gabarre">Jean Gabarre</name>
<affiliation><inist:fA14 i1="12"><s1>Hôpital de la Pitie Salpetriere</s1>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Salles, Bruno" sort="Salles, Bruno" uniqKey="Salles B" first="Bruno" last="Salles">Bruno Salles</name>
<affiliation><inist:fA14 i1="14"><s1>Centre Hospitalier</s1>
<s2>Chalons-Saône</s2>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Den Neste, Eric Van" sort="Den Neste, Eric Van" uniqKey="Den Neste E" first="Eric Van" last="Den Neste">Eric Van Den Neste</name>
<affiliation><inist:fA14 i1="17"><s1>UCL Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Canioni, Danielle" sort="Canioni, Danielle" uniqKey="Canioni D" first="Danielle" last="Canioni">Danielle Canioni</name>
<affiliation><inist:fA14 i1="13"><s1>Hôpital Necker</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garin, Etienne" sort="Garin, Etienne" uniqKey="Garin E" first="Etienne" last="Garin">Etienne Garin</name>
<affiliation><inist:fA14 i1="07"><s1>CHU de Rennes</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fulham, Michael" sort="Fulham, Michael" uniqKey="Fulham M" first="Michael" last="Fulham">Michael Fulham</name>
<affiliation><inist:fA14 i1="02"><s1>Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Borght, Thierry Vander" sort="Borght, Thierry Vander" uniqKey="Borght T" first="Thierry Vander" last="Borght">Thierry Vander Borght</name>
<affiliation><inist:fA14 i1="16"><s1>Universite Catholique de Louvain (UCL), Mont-Godinne Medical Center</s1>
<s2>Yvoir</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name>
<affiliation><inist:fA14 i1="15"><s1>Hospices Civils de Lyon, Universite Lyon1</s1>
<s3>FRA</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0380678</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0380678 INIST</idno>
<idno type="RBID">Pascal:11-0380678</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A24</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants</title>
<author><name sortKey="Trotman, Judith" sort="Trotman, Judith" uniqKey="Trotman J" first="Judith" last="Trotman">Judith Trotman</name>
<affiliation><inist:fA14 i1="01"><s1>Concord Hospital</s1>
<s3>INC</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fournier, Marion" sort="Fournier, Marion" uniqKey="Fournier M" first="Marion" last="Fournier">Marion Fournier</name>
<affiliation><inist:fA14 i1="05"><s1>Hospices Civils de Lyon, Groupe d'Etude des Lymphomes de l'Adulte, Recherche Clinique, Hôpital Lyon sud, Pierre-Benite</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lamy, Thierry" sort="Lamy, Thierry" uniqKey="Lamy T" first="Thierry" last="Lamy">Thierry Lamy</name>
<affiliation><inist:fA14 i1="06"><s1>Centre Hospitalier Universitaire (CHU) de Rennes, L'Institut National de la Sante et de la Recherche Médicale (INSERM) U917, Universite de Rennes</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name>
<affiliation><inist:fA14 i1="03"><s1>Peter MacCallum Cancer Center and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sonet, Anne" sort="Sonet, Anne" uniqKey="Sonet A" first="Anne" last="Sonet">Anne Sonet</name>
<affiliation><inist:fA14 i1="16"><s1>Universite Catholique de Louvain (UCL), Mont-Godinne Medical Center</s1>
<s2>Yvoir</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Janikova, Andrea" sort="Janikova, Andrea" uniqKey="Janikova A" first="Andrea" last="Janikova">Andrea Janikova</name>
<affiliation><inist:fA14 i1="18"><s1>University Hospital Brno</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shpilberg, Ofer" sort="Shpilberg, Ofer" uniqKey="Shpilberg O" first="Ofer" last="Shpilberg">Ofer Shpilberg</name>
<affiliation><inist:fA14 i1="19"><s1>Rabin Medical Center</s1>
<s2>Petah-Tikva</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="20"><s1>Tel Aviv University</s1>
<s2>Tel Aviv</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gyan, Emmanuel" sort="Gyan, Emmanuel" uniqKey="Gyan E" first="Emmanuel" last="Gyan">Emmanuel Gyan</name>
<affiliation><inist:fA14 i1="08"><s1>CHU de Tours</s1>
<s2>Tours</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tilly, Herve" sort="Tilly, Herve" uniqKey="Tilly H" first="Hervé" last="Tilly">Hervé Tilly</name>
<affiliation><inist:fA14 i1="09"><s1>Centre Henri Becquerel, INSERM U918, Universite de Rouen</s1>
<s2>Rouen</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Estell, Jane" sort="Estell, Jane" uniqKey="Estell J" first="Jane" last="Estell">Jane Estell</name>
<affiliation><inist:fA14 i1="01"><s1>Concord Hospital</s1>
<s3>INC</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Forsyth, Cecily" sort="Forsyth, Cecily" uniqKey="Forsyth C" first="Cecily" last="Forsyth">Cecily Forsyth</name>
<affiliation><inist:fA14 i1="04"><s1>Wyong Hospital</s1>
<s2>Kanwal</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Decaudin, Didier" sort="Decaudin, Didier" uniqKey="Decaudin D" first="Didier" last="Decaudin">Didier Decaudin</name>
<affiliation><inist:fA14 i1="10"><s1>Institut Curie</s1>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fabiani, Bettina" sort="Fabiani, Bettina" uniqKey="Fabiani B" first="Bettina" last="Fabiani">Bettina Fabiani</name>
<affiliation><inist:fA14 i1="11"><s1>Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine</s1>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabarre, Jean" sort="Gabarre, Jean" uniqKey="Gabarre J" first="Jean" last="Gabarre">Jean Gabarre</name>
<affiliation><inist:fA14 i1="12"><s1>Hôpital de la Pitie Salpetriere</s1>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Salles, Bruno" sort="Salles, Bruno" uniqKey="Salles B" first="Bruno" last="Salles">Bruno Salles</name>
<affiliation><inist:fA14 i1="14"><s1>Centre Hospitalier</s1>
<s2>Chalons-Saône</s2>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Den Neste, Eric Van" sort="Den Neste, Eric Van" uniqKey="Den Neste E" first="Eric Van" last="Den Neste">Eric Van Den Neste</name>
<affiliation><inist:fA14 i1="17"><s1>UCL Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Canioni, Danielle" sort="Canioni, Danielle" uniqKey="Canioni D" first="Danielle" last="Canioni">Danielle Canioni</name>
<affiliation><inist:fA14 i1="13"><s1>Hôpital Necker</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garin, Etienne" sort="Garin, Etienne" uniqKey="Garin E" first="Etienne" last="Garin">Etienne Garin</name>
<affiliation><inist:fA14 i1="07"><s1>CHU de Rennes</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fulham, Michael" sort="Fulham, Michael" uniqKey="Fulham M" first="Michael" last="Fulham">Michael Fulham</name>
<affiliation><inist:fA14 i1="02"><s1>Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Borght, Thierry Vander" sort="Borght, Thierry Vander" uniqKey="Borght T" first="Thierry Vander" last="Borght">Thierry Vander Borght</name>
<affiliation><inist:fA14 i1="16"><s1>Universite Catholique de Louvain (UCL), Mont-Godinne Medical Center</s1>
<s2>Yvoir</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name>
<affiliation><inist:fA14 i1="15"><s1>Hospices Civils de Lyon, Universite Lyon1</s1>
<s3>FRA</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>B cell neoplasm</term>
<term>Cancerology</term>
<term>Clinical trial</term>
<term>Computerized axial tomography</term>
<term>Emission tomography</term>
<term>Follicular lymphoma</term>
<term>Human</term>
<term>Induction treatment</term>
<term>Lymphoid neoplasm</term>
<term>Positron emission tomography</term>
<term>Prognosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Tomoscintigraphie</term>
<term>Tomographie par émission de positons</term>
<term>Traitement induction</term>
<term>Tomodensitométrie</term>
<term>Homme</term>
<term>Pronostic</term>
<term>Lymphome folliculaire</term>
<term>Essai clinique</term>
<term>Cancérologie</term>
<term>Hémopathie maligne lymphoïde</term>
<term>Hémopathie lymphoïde B</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose The utility of [<sup>18</sup>
F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study. Patients and Methods Results of PET-CT scans performed after induction immunochemotherapy were recorded retrospectively. Patients went on to either observation or rituximab maintenance per protocol independent of the PET-CT result. Patient characteristics and outcomes were then evaluated. Results Of 122 PET-CT scans performed at the end of the induction immunochemotherapy, 32 (26%) were reported as positive by the local investigator. Initial demographic or disease characteristics did not differ between PET-CT-positive (PET-positive) and PET-CT-negative (PET-negative) patients. PET status correlated with conventional response criteria (P<.001). Patients remaining PET positive had a significantly (P< .001) inferior progression-free survival at 42 months of 32.9% (95% CI, 17.2% to 49.5%) compared with 70.7% (95% CI, 59.3% to 79.4%) in those who became PET negative. PET status, but not conventional response (complete response or complete response unconfirmed v partial response) according to IWC 1999, was an independent predictive factor for lymphoma progression. The risk of death was also increased in PET-positive patients (hazard ratio 7.0; P = .0011). Conclusion [<sup>18</sup>
F]FDG PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>29</s2>
</fA05>
<fA06><s2>23</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TROTMAN (Judith)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FOURNIER (Marion)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LAMY (Thierry)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SEYMOUR (John Francis)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SONET (Anne)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>JANIKOVA (Andrea)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SHPILBERG (Ofer)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GYAN (Emmanuel)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TILLY (Hervé)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ESTELL (Jane)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>FORSYTH (Cecily)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>DECAUDIN (Didier)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>FABIANI (Bettina)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>GABARRE (Jean)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>SALLES (Bruno)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>DEN NESTE (Eric Van)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>CANIONI (Danielle)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>GARIN (Etienne)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>FULHAM (Michael)</s1>
</fA11>
<fA11 i1="20" i2="1"><s1>BORGHT (Thierry Vander)</s1>
</fA11>
<fA11 i1="21" i2="1"><s1>SALLES (Gilles)</s1>
</fA11>
<fA14 i1="01"><s1>Concord Hospital</s1>
<s3>INC</s3>
<sZ>1 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney</s1>
<s2>Sydney</s2>
<s3>AUS</s3>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Peter MacCallum Cancer Center and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Wyong Hospital</s1>
<s2>Kanwal</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Hospices Civils de Lyon, Groupe d'Etude des Lymphomes de l'Adulte, Recherche Clinique, Hôpital Lyon sud, Pierre-Benite</s1>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Centre Hospitalier Universitaire (CHU) de Rennes, L'Institut National de la Sante et de la Recherche Médicale (INSERM) U917, Universite de Rennes</s1>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>CHU de Rennes</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>CHU de Tours</s1>
<s2>Tours</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Centre Henri Becquerel, INSERM U918, Universite de Rouen</s1>
<s2>Rouen</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Institut Curie</s1>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine</s1>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Hôpital de la Pitie Salpetriere</s1>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Hôpital Necker</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Centre Hospitalier</s1>
<s2>Chalons-Saône</s2>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Hospices Civils de Lyon, Universite Lyon1</s1>
<s3>FRA</s3>
<sZ>21 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Universite Catholique de Louvain (UCL), Mont-Godinne Medical Center</s1>
<s2>Yvoir</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
<sZ>20 aut.</sZ>
</fA14>
<fA14 i1="17"><s1>UCL Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="18"><s1>University Hospital Brno</s1>
<s2>Brno</s2>
<s3>CZE</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="19"><s1>Rabin Medical Center</s1>
<s2>Petah-Tikva</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="20"><s1>Tel Aviv University</s1>
<s2>Tel Aviv</s2>
<s3>ISR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>3194-3200</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000191138370140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0380678</s0>
</fA47>
<fA60><s1>P</s1>
<s3>C</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose The utility of [<sup>18</sup>
F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study. Patients and Methods Results of PET-CT scans performed after induction immunochemotherapy were recorded retrospectively. Patients went on to either observation or rituximab maintenance per protocol independent of the PET-CT result. Patient characteristics and outcomes were then evaluated. Results Of 122 PET-CT scans performed at the end of the induction immunochemotherapy, 32 (26%) were reported as positive by the local investigator. Initial demographic or disease characteristics did not differ between PET-CT-positive (PET-positive) and PET-CT-negative (PET-negative) patients. PET status correlated with conventional response criteria (P<.001). Patients remaining PET positive had a significantly (P< .001) inferior progression-free survival at 42 months of 32.9% (95% CI, 17.2% to 49.5%) compared with 70.7% (95% CI, 59.3% to 79.4%) in those who became PET negative. PET status, but not conventional response (complete response or complete response unconfirmed v partial response) according to IWC 1999, was an independent predictive factor for lymphoma progression. The risk of death was also increased in PET-positive patients (hazard ratio 7.0; P = .0011). Conclusion [<sup>18</sup>
F]FDG PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B19B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tomographie par émission de positons</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Positron emission tomography</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement induction</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Induction treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento inductivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tomodensitométrie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Computerized axial tomography</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tomodensitometría</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lymphome folliculaire</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Follicular lymphoma</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Linfoma folicular</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Hémopathie lymphoïde B</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>B cell neoplasm</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Imagerie médicale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Medical imagery</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Imaginería médica</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Radiodiagnostic</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Radiodiagnosis</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Radiodiagnóstico</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fN21><s1>262</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0380678 INIST</NO>
<ET>Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants</ET>
<AU>TROTMAN (Judith); FOURNIER (Marion); LAMY (Thierry); SEYMOUR (John Francis); SONET (Anne); JANIKOVA (Andrea); SHPILBERG (Ofer); GYAN (Emmanuel); TILLY (Hervé); ESTELL (Jane); FORSYTH (Cecily); DECAUDIN (Didier); FABIANI (Bettina); GABARRE (Jean); SALLES (Bruno); DEN NESTE (Eric Van); CANIONI (Danielle); GARIN (Etienne); FULHAM (Michael); BORGHT (Thierry Vander); SALLES (Gilles)</AU>
<AF>Concord Hospital/Inconnu (1 aut., 10 aut.); Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney/Sydney/Australie (19 aut.); Peter MacCallum Cancer Center and University of Melbourne/Melbourne/Australie (4 aut.); Wyong Hospital/Kanwal/Australie (11 aut.); Hospices Civils de Lyon, Groupe d'Etude des Lymphomes de l'Adulte, Recherche Clinique, Hôpital Lyon sud, Pierre-Benite/France (2 aut.); Centre Hospitalier Universitaire (CHU) de Rennes, L'Institut National de la Sante et de la Recherche Médicale (INSERM) U917, Universite de Rennes/France (3 aut.); CHU de Rennes/Rennes/France (18 aut.); CHU de Tours/Tours/France (8 aut.); Centre Henri Becquerel, INSERM U918, Universite de Rouen/Rouen/France (9 aut.); Institut Curie/France (12 aut.); Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine/France (13 aut.); Hôpital de la Pitie Salpetriere/France (14 aut.); Hôpital Necker/Paris/France (17 aut.); Centre Hospitalier/Chalons-Saône/France (15 aut.); Hospices Civils de Lyon, Universite Lyon1/France (21 aut.); Universite Catholique de Louvain (UCL), Mont-Godinne Medical Center/Yvoir/France (5 aut., 20 aut.); UCL Saint-Luc/Brussels/Belgique (16 aut.); University Hospital Brno/Brno/Tchèque, République (6 aut.); Rabin Medical Center/Petah-Tikva/Israël (7 aut.); Tel Aviv University/Tel Aviv/Israël (7 aut.)</AF>
<DT>Publication en série; Compte-rendu; Niveau analytique</DT>
<SO>Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2011; Vol. 29; No. 23; Pp. 3194-3200; Bibl. 29 ref.</SO>
<LA>Anglais</LA>
<EA>Purpose The utility of [<sup>18</sup>
F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study. Patients and Methods Results of PET-CT scans performed after induction immunochemotherapy were recorded retrospectively. Patients went on to either observation or rituximab maintenance per protocol independent of the PET-CT result. Patient characteristics and outcomes were then evaluated. Results Of 122 PET-CT scans performed at the end of the induction immunochemotherapy, 32 (26%) were reported as positive by the local investigator. Initial demographic or disease characteristics did not differ between PET-CT-positive (PET-positive) and PET-CT-negative (PET-negative) patients. PET status correlated with conventional response criteria (P<.001). Patients remaining PET positive had a significantly (P< .001) inferior progression-free survival at 42 months of 32.9% (95% CI, 17.2% to 49.5%) compared with 70.7% (95% CI, 59.3% to 79.4%) in those who became PET negative. PET status, but not conventional response (complete response or complete response unconfirmed v partial response) according to IWC 1999, was an independent predictive factor for lymphoma progression. The risk of death was also increased in PET-positive patients (hazard ratio 7.0; P = .0011). Conclusion [<sup>18</sup>
F]FDG PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies.</EA>
<CC>002B04; 002B19B</CC>
<FD>Tomoscintigraphie; Tomographie par émission de positons; Traitement induction; Tomodensitométrie; Homme; Pronostic; Lymphome folliculaire; Essai clinique; Cancérologie; Hémopathie maligne lymphoïde; Hémopathie lymphoïde B</FD>
<FG>Exploration radioisotopique; Imagerie médicale; Radiodiagnostic; Hémopathie maligne; Cancer; Lymphome non hodgkinien; Syndrome lymphoprolifératif</FG>
<ED>Emission tomography; Positron emission tomography; Induction treatment; Computerized axial tomography; Human; Prognosis; Follicular lymphoma; Clinical trial; Cancerology; Lymphoid neoplasm; B cell neoplasm</ED>
<EG>Radionuclide study; Medical imagery; Radiodiagnosis; Malignant hemopathy; Cancer; Non Hodgkin lymphoma; Lymphoproliferative syndrome</EG>
<SD>Tomocentelleografía; Tomografía emisión positrones; Tratamiento inductivo; Tomodensitometría; Hombre; Pronóstico; Linfoma folicular; Ensayo clínico; Cancerología</SD>
<LO>INIST-20094.354000191138370140</LO>
<ID>11-0380678</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:11-0380678 |texte= Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants }}
This area was generated with Dilib version V0.6.33. |